← Back
Outlook Therapeutics
OTLK · listed on Nasdaq · worth $114.23 million
$0.4692
+0.26% on Nov 2
Ten insider buys in the last year, $7.87 million in all. None in the last two weeks.
Different buyers at once4 insiders bought, and CVI Investments reported a new 9.9% stake, within 3 weeks · Aug 19
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
176.6M shares
73% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, seven insiders bought Outlook Therapeutics stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
10% owner
Ghiath M. Sukhtian
Bought $5M on May 28 — 8,539,709 shares at $0.5855, held through a trust or family, 39% of what they now own.
No earlier purchases to measure
Director
Kurt J. Hilzinger
Bought $176.5K on May 26 — 400,000 shares at $0.4413, 94% of what they now own.
First purchase we have on file
Director
Faisal Ghiath Sukhtian
Bought $100K on Jul 29 — 95,398 shares at $1.05, 43% of what they now own.
No earlier purchases to measure
Big investors
People and funds that reported owning 5% or more of Outlook Therapeutics, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company.Empery Asset Management8.7%Oct 13
Filed by someone who owns 5% or more and does not plan to influence the company.CVI Investments9.9%Aug 19
Filed by someone who owns 5% or more and may try to influence how the company is run. · updateGMS Ventures & Investments16.4%Aug 14
All reports
Every insider trade and SEC report we hold for Outlook Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Aug 14BoughtGhiath M. SukhtianAug 14 · Traded Aug 12 · 10% owner+10%via a trust or family2,525,252 @ $0.9900$2.5M
5 more with Pro →Analysts, earnings and news
Analysts' price target
$5.40 average
4 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
0 of 5 quarters above
Q2 '26−$0.09 a share−$0.01
Q1 '26−$0.17 a share−$0.05
Q4 '25−$0.22 a share−$0.05
Q3 '25−$0.29 a share−$0.04